Pharma BD Deal Intelligence

Pfizer Inc. / Anacor Pharmaceuticals, Inc.

2016 · Acquisition/Merger · $5.2B · Complete

Announcement Sentiment

Strongly positive

Pfizer acquired Anacor Pharmaceuticals for $99.25/share cash, ~$5.2B equity value (including net cash assumed). Lead asset crisaborole, a topical PDE-4 inhibitor under FDA review for atopic dermatitis, projected $2B+ peak sales potential. Approved as Eucrisa December 2016. Strategic rationale: build inflammation/immunology franchise.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced May 16, 2016
Closed Jun 24, 2016
Deal value $5.2B
Deal type Acquisition/Merger
Therapeutic area Mild-to-moderate atopic dermatitis (eczema)
Indications Mild-to-moderate atopic dermatitis (eczema)
Key assets Crisaborole (later Eucrisa)
Mechanism Topical phosphodiesterase 4 (PDE-4) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals